PAUL PASTOLERO: Open Payments
NPI 1619329067 · ALLEN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,261 in 62 payments from 19 companies in 2025. Trend: 2023 $425 · 2024 $1,441 · 2025 $1,261
Food & beverage: $1,261
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $220 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $163 |
| Corium, LLC | 5 | $140 |
| Lundbeck LLC | 5 | $91 |
| Noven Therapeutics, LLC | 4 | $86 |
| Neurocrine BioSciences, Inc. | 3 | $83 |
| Teva Pharmaceuticals USA, Inc. | 3 | $63 |
| Janssen Pharmaceuticals, Inc | 3 | $61 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
Products named: VRAYLAR, CAPLYTA, REXULTI, Azstarys, Xelstrym, INGREZZA, AUSTEDO XR, SPRAVATO.
Industry payments across TX — which companies pay providers there.
